Percival, Mary-Elizabeth; Wang, Hai-Lin; Zhang, Mei-Jie; Saber, Wael; de Lima, Marcos; Litzow, Mark; Kebriaei, Partow; Abdel-Azim, Hisham; Adekola, Kehinde; Aljurf, Mahmoud; Bacher, Ulrike; Badawy, Sherif M; Beitinjaneh, Amer; Bejanyan, Nelli; Bhatt, Vijaya; Byrne, Michael; Cahn, Jean-Yves; Castillo, Paul; Chao, Nelson; Chhabra, Saurabh; ... (2021). Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 56(9), pp. 2108-2117. Springer Nature 10.1038/s41409-021-01261-6
Text
Impact_s41409-021-01261-6.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB) |
Acute myeloid leukemia (AML) patients often undergo allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR). We examined the effect of depth of clinical response, including incomplete count recovery (CRi) and/or measurable residual disease (MRD), in patients from the Center for International Blood and Marrow Transplantation Research (CIBMTR) registry. We identified 2492 adult patients (1799 CR and 693 CRi) who underwent alloHCT between January 1, 2007 and December 31, 2015. The primary outcome was overall survival (OS). Multivariable analysis was performed to adjust for patient-, disease-, and transplant-related factors. Baseline characteristics were similar. Patients in CRi compared to those in CR had an increased likelihood of death (HR: 1.27; 95% confidence interval: 1.13-1.43). Compared to CR, CRi was significantly associated with increased non-relapse mortality (NRM), shorter disease-free survival (DFS), and a trend toward increased relapse. Detectable MRD was associated with shorter OS, shorter DFS, higher NRM, and increased relapse compared to absence of MRD. The deleterious effects of CRi and MRD were independent. In this large CIBMTR cohort, survival outcomes differ among AML patients based on depth of CR and presence of MRD at the time of alloHCT. Further studies should focus on optimizing post-alloHCT outcomes for patients with responses less than CR.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Bacher, Vera Ulrike |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1476-5365 |
Publisher: |
Springer Nature |
Language: |
English |
Submitter: |
Pierrette Durand Lüthi |
Date Deposited: |
27 Apr 2021 15:28 |
Last Modified: |
05 Dec 2022 15:51 |
Publisher DOI: |
10.1038/s41409-021-01261-6 |
Related URLs: |
|
PubMed ID: |
33864019 |
BORIS DOI: |
10.48350/156088 |
URI: |
https://boris.unibe.ch/id/eprint/156088 |